Asthma
Conditions
Keywords
Asthma, anti-immunoglobulin E, omalizumab
Brief summary
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
Interventions
DRUGOmalizumab
Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
DRUGLong-acting beta 2-adrenergic agonist (LABA)
Fixed dose of LABA as prescribed prior to study entry
DRUGShort-acting beta 2-adrenergic agonist (SABA)
Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
Sponsors
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 12 to 75 years-old during screening visit. * Body weight \> 20 kg and \< 150 kg. * Daily or persistent asthma symptoms. * Night symptoms at least once a week. * Forced expiratory volume in 1 second (FEV1) \> 40% and \< 80% of predicted normal value and continuing asthma symptoms. * FEV1 increased \> 12% from baseline within 30 minutes of inhaled (up to 400 mcg) or nebulized (up to 5 mg) salbutamol. * Subject taking more than 500 mcg/day of fluticasone or equivalent associated to a long-acting β2-agonist. * Inhaled corticosteroid and long-acting beta-2 adrenergic agonist (LABA) doses that remained fixed during the last 12 weeks prior to screening. * Medical history of at least two episodes of asthma exacerbation treated with systemic corticoid or at least one severe asthma exacerbation treated with systemic corticoid and hospitalization or emergency room visit in the last 12 months prior to screening. * Positive skin prick test (diameter of wheal \> 3mm) to at least one perennial aeroallergen (dust mite, cat/dog dander, cockroaches), to which the subject was likely to be exposed during the study. * Subject capable to read and understand asthma related quality of life questionnaire (Juniper's questionnaire).
Exclusion criteria
* Pregnant, nursing female subjects. * Female subjects without current acceptable contraceptive method. * Previous history of allergy or hypersensitivity to omalizumab. * Subjects with prior treatment with omalizumab. * Subjects with medical history of psychiatric disorder. * Subject had been treated with systemic corticosteroid for any reason other than asthma. * Subject took β2 antagonist medication in the last 3 months prior to screening visit. * Subject took protocol prohibited medication prior to screening. * Medical history of food or drug related severe anaphylactoid reactions. * Medical history of antibiotics allergy. Patients were included if the antibiotics to which they were allergic to were to be avoided for the entire duration of the study. * Asthma related to non-steroidal anti-inflammatory drug (NSAID). * Treatment of exacerbation in the 4 weeks prior to randomization. * Other active lung diseases. * Medical history of others uncontrolled diseases 3 months prior randomization (eg, infections, coronary heart diseases and metabolic diseases). * Any history of cancer. * Abnormal electrocardiogram (ECG), laboratory exams (clinically significant abnormalities), and chest X-ray (CXR). * Evidence or history of drug or alcohol abuse. * Airway infection (eg, pneumonia, acute sinusitis) 4 weeks prior to screening visit. * Smokers or smoking history of \> 10 pack-years. * Subject that had been treated with investigational drugs over the past 30 days or during the course of the trial. * Subject had elevated IgE levels for reasons other than allergy. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ) | Baseline and Week 20 | The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and a score of 1.0 indicates severe impairment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20 | Baseline and Week 20 | The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. AQLQ of each domain is the mean of the responses to each of the questions within that domain. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment. |
| The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Baseline and Week 20 | AQLQ was administered to all patients at Baseline, Week 12 and Week 20, and prior to any clinic visit evaluation and drug administration. The 32 questions in the AQLQ were divided into four domains: activity limitations, symptoms, emotional function, and environmental stimuli. AQLQ domain scores were calculated by adding the responses to each of the questions in the domain and dividing by the number of questions in the domain. Each domain score was between 1 and 7. Score 7.0 meant that the patient had no impairments due to asthma and score 1.0 indicated severe impairment. |
| Number of Asthma Exacerbation Episodes Per Participant | From Baseline through 20 weeks | For the purpose of evaluating efficacy, a clinically significant asthma exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling the baseline ICS dose for at least 3 days and/or treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the above corticosteroid regimens marked the start of an asthma exacerbation episode and cessation of the additional corticosteroid regimens marked the end of an exacerbation episode. |
| Percentage of Participants Using Rescue Medication | From Baseline through 20 Weeks | When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. |
| Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks | Baseline and Week 20 | The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment. |
| Mean Number of Puffs of Rescue Medication Taken Per Day | From Baseline through 20 Weeks | When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. The number of puffs taken during each 24 hour period was recorded in the patient dairy. The total number of puffs over 20 weeks of treatment was divided by the number of treatment days (140 days) to calculate the mean number of puffs per day. |
| Physician's Global Assessment of Treatment Effectiveness | 20 Weeks | At the end of Week 20 a global evaluation of the treatment effectiveness was performed by the investigator using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma |
| Patient's Global Assessment of Treatment Effectiveness | 20 Weeks | At the end of Week 20, a global evaluation of the treatment effectiveness was performed by the patient using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma |
| Free Days With no Rescue Medication | From Baseline through 20 weeks (140 days) | When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. Days with no rescue medication intake were the variable of interest for this analysis. |
Countries
Brazil
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Omalizumab + Conventional Therapy Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit. | 78 |
| Conventional Therapy Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit. | 38 |
| Total | 116 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Administrative issues | 1 | 0 |
| Overall Study | Adverse Event | 2 | 0 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Medical Decision | 0 | 1 |
| Overall Study | Non-adherence to protocol | 0 | 1 |
| Overall Study | Pregnancy | 1 | 0 |
| Overall Study | Protocol Violation | 4 | 1 |
Baseline characteristics
| Characteristic | Omalizumab + Conventional Therapy | Conventional Therapy | Total |
|---|---|---|---|
| Age, Customized > 12 years and < 25 years | 4 Participants 13.1 | 4 Participants 12.8 | 8 Participants |
| Age, Customized ≥ 25 and < 35 years | 15 Participants | 3 Participants | 18 Participants |
| Age, Customized ≥ 35 and < 55 years | 42 Participants | 23 Participants | 65 Participants |
| Age, Customized ≥ 55 and < 65 years | 12 Participants | 4 Participants | 16 Participants |
| Age, Customized ≥ 65 and < 75 years | 5 Participants | 4 Participants | 9 Participants |
| Sex: Female, Male Female | 60 Participants | 29 Participants | 89 Participants |
| Sex: Female, Male Male | 18 Participants | 9 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 42 / 78 | 16 / 38 |
| serious Total, serious adverse events | 3 / 78 | 0 / 38 |
Outcome results
Primary
The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ)
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and a score of 1.0 indicates severe impairment.
Time frame: Baseline and Week 20
Population: Patients who took at least one dose of double-blind study drug and who had at least one post-baseline safety or efficacy assessment made up the intent-to treat (ITT) population. Last observation carried forward (LOCF) approach was used. Scores of completed AQLQ at Week 12 were used at Week 20 for dropped out patients or for missing values.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Omalizumab + Conventional Therapy | The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ) | Baseline (n=77, 37) | 3.1 Units on a scale | Standard Error 1 |
| Omalizumab + Conventional Therapy | The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ) | At Week 20 (n=78, 36) | 4.4 Units on a scale | Standard Error 1.4 |
| Omalizumab + Conventional Therapy | The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ) | Change from baseline to week 20 (n=77, 36) | 1.2 Units on a scale | Standard Error 0.1 |
| Conventional Therapy | The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ) | Baseline (n=77, 37) | 3.1 Units on a scale | Standard Error 1.1 |
| Conventional Therapy | The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ) | At Week 20 (n=78, 36) | 3.0 Units on a scale | Standard Error 1.1 |
| Conventional Therapy | The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ) | Change from baseline to week 20 (n=77, 36) | -0.1 Units on a scale | Standard Error 0.1 |
Secondary
Free Days With no Rescue Medication
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. Days with no rescue medication intake were the variable of interest for this analysis.
Time frame: From Baseline through 20 weeks (140 days)
Population: All randomized patients who took at least one dose of double-blind study medication and who had at least one post-baseline safety or efficacy assessment made up the intention-to-treat (ITT) population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Omalizumab + Conventional Therapy | Free Days With no Rescue Medication | 73.5 Days | Standard Deviation 39.4 |
| Conventional Therapy | Free Days With no Rescue Medication | 74.9 Days | Standard Deviation 35.4 |
Secondary
Mean Number of Puffs of Rescue Medication Taken Per Day
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. The number of puffs taken during each 24 hour period was recorded in the patient dairy. The total number of puffs over 20 weeks of treatment was divided by the number of treatment days (140 days) to calculate the mean number of puffs per day.
Time frame: From Baseline through 20 Weeks
Population: All randomized patients who took at least one dose of double-blind study medication and who had at least one post-baseline safety or efficacy assessment made up the intention-to-treat (ITT) population. Number of patients analyzed includes only those patients requiring rescue medication during the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Omalizumab + Conventional Therapy | Mean Number of Puffs of Rescue Medication Taken Per Day | 5.5 Puffs | Standard Deviation 4.1 |
| Conventional Therapy | Mean Number of Puffs of Rescue Medication Taken Per Day | 6.4 Puffs | Standard Deviation 4.7 |
Secondary
Number of Asthma Exacerbation Episodes Per Participant
For the purpose of evaluating efficacy, a clinically significant asthma exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling the baseline ICS dose for at least 3 days and/or treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the above corticosteroid regimens marked the start of an asthma exacerbation episode and cessation of the additional corticosteroid regimens marked the end of an exacerbation episode.
Time frame: From Baseline through 20 weeks
Population: All randomized patients who took at least one dose of double-blind study medication and who had at least one post-baseline safety or efficacy assessment made up the ITT population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Omalizumab + Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 2 episodes | 5 Participants |
| Omalizumab + Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 4 episodes | 1 Participants |
| Omalizumab + Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 3 episodes | 3 Participants |
| Omalizumab + Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Total number of patients with episodes | 34 Participants |
| Omalizumab + Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 1 episode | 25 Participants |
| Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Total number of patients with episodes | 20 Participants |
| Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 1 episode | 12 Participants |
| Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 2 episodes | 6 Participants |
| Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 3 episodes | 1 Participants |
| Conventional Therapy | Number of Asthma Exacerbation Episodes Per Participant | Patients with 4 episodes | 1 Participants |
Secondary
Patient's Global Assessment of Treatment Effectiveness
At the end of Week 20, a global evaluation of the treatment effectiveness was performed by the patient using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma
Time frame: 20 Weeks
Population: All randomized patients who took at least one dose of double-blind study medication and who had at least one post-baseline safety or efficacy assessment made up the ITT population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Omalizumab + Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Good | 30 Participants |
| Omalizumab + Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Poor | 3 Participants |
| Omalizumab + Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Moderate | 10 Participants |
| Omalizumab + Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Worsening | 0 Participants |
| Omalizumab + Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Excellent | 33 Participants |
| Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Worsening | 2 Participants |
| Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Excellent | 3 Participants |
| Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Good | 13 Participants |
| Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Moderate | 10 Participants |
| Conventional Therapy | Patient's Global Assessment of Treatment Effectiveness | Poor | 9 Participants |
Secondary
Percentage of Participants Using Rescue Medication
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm.
Time frame: From Baseline through 20 Weeks
Population: All randomized patients who took at least one dose of double-blind study medication and who had at least one post-baseline safety or efficacy assessment made up the intention-to-treat (ITT) population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Omalizumab + Conventional Therapy | Percentage of Participants Using Rescue Medication | 43.6 Percentage of participants |
| Conventional Therapy | Percentage of Participants Using Rescue Medication | 44.7 Percentage of participants |
Secondary
Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. AQLQ of each domain is the mean of the responses to each of the questions within that domain. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.
Time frame: Baseline and Week 20
Population: Patients who took at least one dose of double-blind study drug and who had at least one post-baseline safety or efficacy assessment made up the intent-to treat (ITT) population. Last observation carried forward (LOCF) approach was used. Scores of completed AQLQ at Week 12 were used at Week 20 for dropped out patients or for missing values.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Omalizumab + Conventional Therapy | Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20 | 70.1 Percentage of participants |
| Conventional Therapy | Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20 | 22.2 Percentage of participants |
Secondary
Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.
Time frame: Baseline and Week 20
Population: Patients who took at least one dose of double-blind study drug and who had at least one post-baseline safety or efficacy assessment made up the intent-to treat (ITT) population. Last observation carried forward (LOCF) approach was used. Scores of completed AQLQ at Week 12 were used at Week 20 for dropped out patients or for missing values.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Omalizumab + Conventional Therapy | Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks | 40.3 Percentage of participants |
| Conventional Therapy | Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks | 2.8 Percentage of participants |
Secondary
Physician's Global Assessment of Treatment Effectiveness
At the end of Week 20 a global evaluation of the treatment effectiveness was performed by the investigator using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma
Time frame: 20 Weeks
Population: All randomized patients who took at least one dose of double-blind study medication and who had at least one post-baseline safety or efficacy assessment made up the intention-to-treat (ITT) population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Omalizumab + Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Good | 35 Participants |
| Omalizumab + Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Poor | 6 Participants |
| Omalizumab + Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Moderate | 13 Participants |
| Omalizumab + Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Worsening | 0 Participants |
| Omalizumab + Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Excellent | 22 Participants |
| Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Worsening | 2 Participants |
| Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Excellent | 2 Participants |
| Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Good | 4 Participants |
| Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Moderate | 11 Participants |
| Conventional Therapy | Physician's Global Assessment of Treatment Effectiveness | Poor | 18 Participants |
Secondary
The Mean Change From Baseline to the End of Study in AQLQ Domain Score
AQLQ was administered to all patients at Baseline, Week 12 and Week 20, and prior to any clinic visit evaluation and drug administration. The 32 questions in the AQLQ were divided into four domains: activity limitations, symptoms, emotional function, and environmental stimuli. AQLQ domain scores were calculated by adding the responses to each of the questions in the domain and dividing by the number of questions in the domain. Each domain score was between 1 and 7. Score 7.0 meant that the patient had no impairments due to asthma and score 1.0 indicated severe impairment.
Time frame: Baseline and Week 20
Population: Patients who took at least one dose of double-blind study drug and who had at least one post-baseline safety or efficacy assessment made up the intent-to treat (ITT) population. Last observation carried forward (LOCF) approach was used. Scores of completed AQLQ at Week 12 were used at Week 20 for dropped out patients or for missing values.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Omalizumab + Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Activity limitation score | 1.3 Units on a scale | Standard Error 0.1 |
| Omalizumab + Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Symptoms score | 1.2 Units on a scale | Standard Error 0.2 |
| Omalizumab + Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Emotional function score | 1.3 Units on a scale | Standard Error 0.2 |
| Omalizumab + Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Environmental stimuli score | 1.2 Units on a scale | Standard Error 0.2 |
| Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Environmental stimuli score | 0.0 Units on a scale | Standard Error 0.2 |
| Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Activity limitation score | -0.2 Units on a scale | Standard Error 0.1 |
| Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Emotional function score | 0.0 Units on a scale | Standard Error 0.1 |
| Conventional Therapy | The Mean Change From Baseline to the End of Study in AQLQ Domain Score | Symptoms score | -0.2 Units on a scale | Standard Error 0.2 |